Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Biden’s CUREIT initiative aims to develop a toolbox of technologies to fight cancer, autoimmune disorders and infectious diseases.
Researchers are working on vaccines that will target multiple flu or coronavirus strains.
Moderna and Merck’s customized neoantigen vaccine plus Keytruda lowered the risk for metastasis or death by 65%.
Experimental flu vaccine, designed to elicit immunity against a broad range of influenza viruses, performed well in a small trial.
Moderna and Merck’s personalized neoantigen vaccine plus checkpoint inhibitor lowered the risk of disease progression after surgery by 44%.
A vaccine using mRNA technology induced an immune response in mice and ferrets against 20 different types of influenza.
A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.
Novel therapies, improved technologies and a better understanding of the immune system could yield broad dividends.
The experimental vaccines use the same technology as the highly effective Moderna COVID-19 shot.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.